<DOC>
	<DOC>NCT02574637</DOC>
	<brief_summary>A Phase 2b study to evaluate the efficacy and safety of MEDI2070 in Subjects with Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy</brief_summary>
	<brief_title>Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease</brief_title>
	<detailed_description>This is a four-part Phase 2b study comprised of a 16-week, double-blind, placebo-controlled, Induction Period, a 12-week double-blind, placebo-controlled, Maintenance Period, a 24-week, Open-label Period and a post-treatment 28 week observational safety follow-up period designed to evaluate the short-term efficacy and the short- and long term safety of MEDI2070 in subjects with moderate to severe, active CD who have failed or are intolerant to anti-TNFα therapy as determined by the Investigator.</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Diagnosis of ileal, ileocolonic, or colonic Crohn's Disease (CD) for &gt; 3 months prior to screening Men or women age 18 80 years at the time of screening Moderate to severely active CD, as defined by Crohn's Disease Activity Index (CDAI) AND endoscopic demonstration of inflammation Stable dose of medications for Crohn's disease therapy Prior treatment failure or intolerance with at least one Anti Tumor Necrosis FactorAlpha Therapy (antiTNF α) agent. Effective contraception from screening, and for 36 weeks after the last dose of investigational product No known history of active tuberculosis (TB) &amp; negative assessment for TB/latent TB Severe underlying immunosuppression Severe gastrointestinal complications; e.g., short bowel syndromes, obstructing strictures, recent or planned bowel surgery, Ileostomy and/or colostomy, recent bowel perforation Significant infections at screening; Infected abscess, positive for Clostridium difficile, recent infectious hospitalization, Recent treatment with approved or investigational biologic therapy for Crohn's disease Recent or planned live attenuated vaccine History of cancer, except for basal cell carcinoma or CIS of the cervix with apparent cure ≥ 12 months before screening Pregnancy/breast feeding Drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MEDI2070</keyword>
	<keyword>inflammatory bowel disease</keyword>
	<keyword>moderate to severe Crohn's Disease</keyword>
	<keyword>IL-23</keyword>
</DOC>